Evidence map›Paper›PMID 17916540›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2007

The narcotic bowel syndrome: clinical features, pathophysiology, and management.

David M S Grunkemeier, Joseph E Cassara, Christine B Dalton, Douglas A Drossman

Open access · greenAbstract readCase Reports
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Lifestyle Factors and Silent Inflammatory Bowel Disease.Inflammatory intestinal diseases · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

David M S GrunkemeierDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Joseph E Cassara
Christine B Dalton
Douglas A Drossman
University of North Carolina at Chapel Hill · US

Funding

Gastrointestinal Biopsychosocial Research CenterR24DK067674 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WHITEHEAD, WILLIAM E · 2004 to 2008
$4.5M
MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERSR01DK049334 · NIDDK · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI DROSSMAN, DOUGLAS A · 1995 to 2001
$1.5M
NIDDK NIH HHS R01 DK049334NIDDK NIH HHS R24 DK067674
6 · The paper itself

Abstract

Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics. This syndrome is underrecognized and may be becoming more prevalent. In the United States this may be the result of increases in using narcotics for chronic nonmalignant painful disorders, and the development of maladaptive therapeutic interactions around its use. NBS can occur in patients with no prior gastrointestinal disorder who receive high dosages of narcotics after surgery or acute painful problems, and among patients with functional gastrointestinal disorders or other chronic gastrointestinal diseases who are managed by physicians who are unaware of the hyperalgesic effects of chronic opioids. The evidence for the enhanced pain perception is based on the following: (1) activation of excitatory antianalgesic pathways within a bimodal opioid regulation system, (2) descending facilitation of pain at the rostral ventral medulla and pain facilitation via dynorphin and cholecystokinin activation, and (3) glial cell activation that produces morphine tolerance and enhances opioid-induced pain. Treatment involves early recognition of the syndrome, an effective physician-patient relationship, graded withdrawal of the narcotic according to a specified withdrawal program, and the institution of medications to reduce withdrawal effects.

Indexed as

AdultDiagnosis, DifferentialFemaleGastrointestinal DiseasesGastrointestinal MotilityHumansNarcoticsPhysician-Patient RelationsSubstance-Related DisordersSyndromeNarcotics

Identifiers

PMID17916540
PMCPMC2074872
OpenAlexW2123607152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.